Microba Life SciencesASX:MAP -2.50% PS Ratio is 1.34 as of Jul. 03, 2026, which is 85% below its 10-year median of 8.79. The stock has 6 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Microba Life Sciences ranks better than 74% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Microba Life Sciences's share price is A$0.039.
Microba Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.03. Hence, Microba Life Sciences's PS Ratio for today is 1.34.
Good Sign:
Microba Life Sciences Ltd stock PS Ratio (=1.14) is close to 5-year low of 1.06.
The historical rank and industry rank for Microba Life Sciences's PS Ratio or its related term are showing as below:
ASX:MAP'
s PS Ratio Range Over the Past 10 Years
Min: 1.06 Med: 8.79 Max: 23
Current: 1.35
During the past 4 years, Microba Life Sciences's highest PS Ratio was 23.00. The lowest was 1.06. And the median was 8.79.
ASX:MAP's PS Ratio is ranked better than 74% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.825
vs ASX:MAP: 1.35
During the past 4 years, Microba Life Sciences's highest 3-Year average Revenue per Share Growth Rate was 20.50% per year. The lowest was 20.50% per year. And the median was 20.50% per year.
Back to Basics: PS Ratio
Microba Life Sciences (ASX:MAP) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Microba Life Sciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's PS Ratio distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Microba Life Sciences's Share Price of today is A$0.039.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Microba Life Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Microba Life Sciences (ASX:MAP) has a PS Ratio of 1.34 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Microba Life Sciences and its competitors. This is 85% below median its historical median of 8.79. Over the past decade, Microba Life Sciences' PS Ratio has ranged from 1.06 to 23.00. According to the industry distribution chart, Microba Life Sciences ranks #52 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 26%.
Is Microba Life Sciences' PS Ratio too high?
Microba Life Sciences' current PS Ratio of 1.34 is 85% below median its 10-year median of 8.79. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 23.00. The Medical Diagnostics & Research industry median PS Ratio is 2.83. Microba Life Sciences' value of 1.34 is 52.6% below this industry median. Based on the distribution chart, Microba Life Sciences ranks #52 out of 200 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Microba Life Sciences' PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #52 out of 200 companies for PS Ratio. This puts Microba Life Sciences in the upper half of its industry. The industry median PS Ratio is 2.83. Microba Life Sciences' value of 1.34 is 52.6% below this benchmark. Historically, Microba Life Sciences' own PS Ratio has ranged from 1.06 to 23.00 over the past decade. While the company's 10-year median is 8.79 vs. the industry median of 2.83, Microba Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.83, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Microba Life Sciences's current PS Ratio of 1.34 is 52.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current PS Ratio is 1.34, which is 85% below median its own 10-year median of 8.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 84.4% below its estimated fair value. The current PS Ratio is 1.34, which is 85% below median its 10-year median of 8.79 and 52.6% below the Medical Diagnostics & Research industry median of 2.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current PS Ratio is 1.34 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 